A myeloproliferative disorder (now more commonly called a myeloproliferative neoplasm, or MPN) is a group of blood cancers in which the bone marrow produces too many of one or more types of blood cells. The overproduction can involve red blood cells, white blood cells, or platelets, and the specific type depends on which cell line is affected. MPNs are relatively uncommon, with the two most frequent subtypes each occurring at a rate of roughly 1.5 per 100,000 people per year in the United States.
How MPNs Develop
Your bone marrow is essentially a blood cell factory, constantly producing red cells, white cells, and platelets in carefully regulated quantities. In an MPN, a genetic mutation in a bone marrow stem cell disrupts that regulation, causing one or more cell types to be churned out in excess. The cells themselves often function normally at first, which is why MPNs can go undetected for years before symptoms appear.
The most common genetic driver is a mutation in a gene called JAK2, which acts like a stuck “on” switch for cell production. This mutation appears in roughly 40 to 60 percent of patients depending on the subtype. Two other mutations, in genes called CALR and MPL, account for additional cases. About 28 percent of patients with essential thrombocythemia carry a CALR mutation, for instance, while MPL mutations are far rarer at around 1 percent. Some patients carry none of these three mutations and are referred to as “triple-negative,” which can complicate diagnosis.
The Main Subtypes
The World Health Organization recognizes seven subcategories of MPN. Three of them are the most common and the ones most people encounter:
- Polycythemia vera (PV) involves overproduction of red blood cells, which thickens the blood and raises the risk of clotting. It occurs in about 1.57 per 100,000 people per year. Over 60 percent of PV patients carry the JAK2 V617F mutation, and nearly all carry some form of JAK2 abnormality.
- Essential thrombocythemia (ET) involves overproduction of platelets, the cell fragments responsible for clotting. Its incidence is about 1.55 per 100,000 per year, making it roughly as common as PV. ET has the broadest spread of mutations: about 40 percent JAK2, 28 percent CALR, and a small number with MPL.
- Primary myelofibrosis (PMF) is the most serious of the three. The bone marrow gradually replaces itself with scar tissue (fibrosis), which impairs its ability to produce normal blood cells. PMF is less common, at about 0.44 per 100,000 per year, and carries the worst prognosis.
The remaining subtypes include chronic myeloid leukemia (CML), which is driven by a distinct genetic abnormality and treated very differently, along with rarer conditions like chronic neutrophilic leukemia and chronic eosinophilic leukemia.
Symptoms and Daily Impact
MPNs are notorious for causing a heavy symptom burden that can significantly affect quality of life, even when blood counts look relatively stable. In a large international survey of over 1,400 MPN patients, the most frequently reported symptoms were:
- Fatigue: reported by 89 percent of patients, making it by far the most common complaint
- Feeling full quickly after eating (early satiety): 64 percent
- Difficulty concentrating: 63 percent
- Reduced physical activity: 62 percent
- Abdominal discomfort: 54 percent
- Night sweats: 53 percent
- Itching: 53 percent
- Bone pain: 49 percent
The abdominal symptoms often stem from an enlarged spleen. Because the spleen helps filter blood cells, it can swell dramatically when the bone marrow is overproducing them, pressing on the stomach and causing discomfort or early fullness. The itching, particularly after a warm shower, is a hallmark of polycythemia vera and is thought to relate to the release of certain chemicals from excess blood cells.
Many patients describe the fatigue as fundamentally different from normal tiredness. It persists regardless of rest and is often the symptom that most limits daily functioning, even more so than pain.
Serious Complications
The most significant risk for MPN patients is abnormal blood clotting. In a large nationwide study with a median follow-up of nearly eight years, 30 percent of MPN patients developed an arterial clot (such as a heart attack or stroke), compared to 19 percent of matched controls. Venous clots, like deep vein thrombosis or pulmonary embolism, occurred in about 12 percent of MPN patients versus 6 percent of controls. Overall, MPN roughly doubles the risk of venous thrombosis.
The other major concern is transformation to a more aggressive blood cancer. About 5 percent of MPN patients develop acute leukemia, with a 10-year cumulative incidence of 6.2 percent. This risk is highest in myelofibrosis and lowest in essential thrombocythemia. PV and ET can also progress into myelofibrosis over time, a process called “secondary myelofibrosis,” which carries the same challenges as primary myelofibrosis.
How MPNs Are Diagnosed
Diagnosis typically begins with routine blood work that reveals abnormal counts, sometimes discovered incidentally during a checkup. Polycythemia vera, for example, is flagged when hemoglobin levels exceed certain thresholds (165 g/L in men, 160 g/L in women) or when the percentage of blood volume occupied by red cells rises above 49 percent in men or 48 percent in women.
Blood tests alone aren’t enough to confirm the diagnosis. A bone marrow biopsy is a central part of the workup. Pathologists examine the marrow for specific patterns: overall cellularity, the types and proportions of cells present, and how much scar tissue has formed. The appearance of megakaryocytes, the large cells that produce platelets, is particularly important. Their number, size, shape, and location within the marrow differ between subtypes and are often the single most defining feature under the microscope.
Genetic testing for the JAK2, CALR, and MPL mutations rounds out the diagnostic picture. Finding one of these mutations in the right clinical context can confirm the diagnosis, while their absence requires the medical team to rule out other causes of abnormal blood counts more carefully.
Treatment and Management
Treatment varies considerably by subtype, risk level, and symptoms. The overarching goals are to reduce the risk of clotting, control symptoms, and slow disease progression.
For polycythemia vera, the most immediate intervention is phlebotomy, which is essentially a blood draw designed to reduce the volume of red blood cells. The target is to keep the hematocrit (the proportion of blood made up of red cells) below 45 percent in men and below 42 percent in women. Many patients with PV need phlebotomy regularly, sometimes every few weeks, alongside low-dose aspirin to reduce clot risk.
For essential thrombocythemia, low-risk patients (younger, no history of clotting) may need only monitoring and aspirin. Higher-risk patients typically take medications that suppress platelet production.
Primary myelofibrosis is the most difficult to treat. The only potentially curative option is a stem cell transplant from a donor, which carries significant risks and is generally reserved for younger patients with aggressive disease. For everyone else, treatment focuses on managing symptoms and complications.
JAK Inhibitors
A class of targeted therapies called JAK inhibitors has transformed MPN management over the past decade. These drugs work by blocking the overactive signaling pathway driven by the JAK2 mutation. The first, ruxolitinib, was approved in 2011 for myelofibrosis and later in 2014 for polycythemia vera. Two additional JAK inhibitors, fedratinib (approved 2019) and pacritinib, are now available specifically for myelofibrosis. These drugs are particularly effective at shrinking an enlarged spleen and reducing symptom burden, though they do not eliminate the underlying disease.
Life Expectancy and Outlook
Prognosis varies widely by subtype. Essential thrombocythemia generally has the best outlook, with many patients living near-normal lifespans when well managed. Polycythemia vera carries a median survival of about 14 years from diagnosis, though many patients live considerably longer, especially when diagnosed at younger ages. Primary myelofibrosis has the shortest median survival, typically ranging from about 3.5 to 7 years depending on risk category, though outcomes have improved with newer treatments.
Age at diagnosis, the specific mutation involved, blood count values, and whether the disease has caused significant fibrosis all factor into individual prognosis. Triple-negative myelofibrosis patients (those without JAK2, CALR, or MPL mutations) tend to have worse outcomes than those with a CALR mutation, who generally fare the best among myelofibrosis patients. Your hematologist will use scoring systems that weigh these factors to estimate risk and guide treatment decisions.